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ABSTRACT
Background    The epidermal growth factor receptor 
(EGFR) is a therapeutic target for patients with non-
small cell lung cancer (NSCLC). Cetuximab is an 
anti-EGFR monoclonal antibody that inhibits EGFR 
signaling and proliferation of colorectal cancer and head 
and neck cancers. Since only few NSCLC patients ben-
efit from cetuximab therapy, we evaluated a novel com-
bination treatment using cetuximab and EGFR small 
interfering RNA (siRNA) to strongly suppress EGFR 
signaling and searched for a biomarker in NSCLC cell 
lines harboring wild-type EGFR.
Methods    Alterations in EGFR and its downstream 
genes in five NSCLC cell lines (A549, Lu99, 86-2, Sq19 
and Ma10) were assessed through sequencing. The pro-
tein expression levels of these molecules were assessed 
through western blotting. The effect of combination 
treatment was determined through cell proliferation 
assay, caspase-3/7 assay, invasion assay, and migration 
assay.
Results    All cell lines were harboring wild-type 
EGFR, whereas KRAS, PTEN, TP53 and LKB1 were 
mutated in A549 and Lu99; Lu99 and Sq19; Lu99, 86-2, 
Sq19 and Ma10; and A549, 86-2, and Sq19 cell lines, re-
spectively. PTEN was not expressed in Sq19, and LKB1 
was not expressed in both A549 and Sq19. TP53 was not 
expressed in both A549 and Lu99. The combination of 
cetuximab and EGFR siRNA significantly suppressed 
cell proliferation in 86-2, Sq19 and Ma10, which express 
wild-type KRAS. It induced apoptosis in A549, 86-2 and 
Ma10 cells, which express wild type PTEN. The combi-
nation treatment had no effect either on cell invasion nor 
migration in all cell lines.
Conclusion    EGFR targeted therapy using the com-
bination of cetuximab and EGFR siRNA is effective in 
NSCLC cell lines harboring wild-type EGFR. Wild-type 
KRAS may act as a potential biomarker for response to 
combination treatment by the induction of apoptosis in 
cells with wild-type PTEN.
Key words    cetuximab; EGFR siRNA; KRAS; non-
small cell lung cancer
Human lung cancer is the leading cause of cancer 
deaths worldwide. Lung cancer is classified into small 
cell lung cancer (SCLC) and NSCLC, accounting for 
approximately 15–20% and 80–85%, respectively. In 
addition, NSCLC is further classified into adenocarcino-
ma, squamous cell carcinoma and large cell carcinoma. 
NSCLC is difficult to treat compared with SCLC.1 
EGFR is transmembrane protein that regulates cell pro-
liferation, apoptosis, angiogenesis and metastasis. EGFR 
is activated by EGF binding, which further activates the 
EGFR downstream signaling pathway.2 In lung cancer, 
overexpression and mutation of EGFR was observed in 
NSCLC patients, which makes it an important therapeu-
tic target. Studies reveal that EGFR mutations occur in 
30–40% of NSCLC patients.3
 Currently, two classes of EGFR targeted drugs are 
used to treat cancers. One of them is EGFR-tyrosine 
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kinase inhibitors (TKIs) and the other is anti-EGFR 
monoclonal antibodies. In lung cancer, EGFR-TKIs 
are the predominantly used EGFR-targeted drugs,4 
and first-generation EGFR-TKIs such as gefitinib and 
erlotinib are recommended for first-line treatment in 
NSCLC patients with EGFR mutations.5 However, 
anti-EGFR monoclonal antibodies, such as cetuximab, 
are not used in NSCLC patients, although they are 
broadly used in patients with colorectal cancer and head 
and neck cancers.6 A randomized, multicenter, phase 
III study [First-Line ErbituX (FLEX)] of cetuximab re-
vealed improvements in the overall survival of NSCLC 
patients.7 However, survival upon addition of cetuximab 
to conventional chemotherapy was only prolonged by 
one month and was considered insignificant compared 
with the cost of treatment. Therefore, novel combination 
therapies with cetuximab and biomarkers to identify 
patients who would benefit from the therapy have been 
extensively sought.8
 RNA interference (RNAi) is a novel strategy that 
degrades the target mRNA by small interfering RNA 
(siRNA) consisting of 19–25 base pair, which leads to 
the down regulation of protein expression.9 In various 
fields such as medicine, biology and engineering, RNAi 
has been widely used as a tool for gene functional 
analysis.10–12 Recently, Food and Drug Administration 
(FDA) approved the first-ever therapeutic drug based on 
siRNA.13 Therefore, inhibition of specific molecules by 
siRNA is now a promising therapy in the cancer.
 In the previous study, we found that NSCLC cell 
lines with EGFR mutation and lack of AKT activation 
were sensitive for cetuximab monotherapy.14 One pos-
sible mechanism of this phenomenon is that these cells 
might become physiologically dependent on EGFR 
signaling pathway for their growth,15 therefore they are 
sensitive for the inhibition of EGFR function by cetux-
imab. There is no report on overcoming the resistance of 
NSCLC cells with wild type EGFR to cetuximab.
 In this study, we developed a novel combination 
treatment using cetuximab and EGFR siRNA to strong-
ly suppress EGFR signaling pathways and studied its 
effect on NSCLC cell lines harboring wild-type EGFR. 
Additionally, we explored candidate gene alterations 
in cells showing response to treatment to find possible 
biomarkers for this combination treatment.
MATERIALS AND METHODS
Cell lines
Human NSCLC cell lines including the adenocarcinoma 
cell lines A549 and Ma10, the squamous cell carcinoma 
cell line Sq19, the giant cell carcinoma cell line Lu99, 
and the large cell carcinoma cell line 86-2 were used 
in this study. A549 was purchased from the American 
Type Culture Collection (ATCC, Manassas, VA). Sq19, 
Lu99, RERF-LC-AI and 86-2 were provided by the 
Riken Cell Bank (Riken, Tsukuba, Japan). The cell 
lines were cultured in Roswell Park Memorial Institute 
(RPMI) 1640 medium or Dulbecco’s modified Eagle’s 
medium (D-MEM) (Wako, Osaka, Japan) supplemented 
with 10% fetal bovine serum(FBS), 100 U/ml penicillin 
G, and 0.1 mg/ml streptomycin at 37℃ in a humidified 
incubator containing 5% CO2. The gene status of cell 
lines that were not published in literature was deter-
mined using polymerase chain reaction (PCR) and direct 
sequencing.16
EGFR siRNA transfection
The EGFR siRNA (sense: 5’-CUCUGGAGGAAAAGAAAGU-
3’ and antisense: 5’-ACUUUCUUUUCCUCCAGAG-3’) 
and the negative control siRNA (no information disclo-
sure) were purchased from Santa Cruz Biotechnology 
(Santa Cruz Biotechnology, Dallas, TX). The cell lines 
were transfected with 10 nM siRNA using Lipofectamine 
3000 (Invitrogen, Carlsbad, CA). Transfection was 
performed according to the manufacturer’s protocol.
Western blotting
After the cell lines were transfected with siRNA, cells 
were collected and washed with phosphate-buffered 
saline (PBS) (-), and subsequently lysed in a lysis 
buffer. The sample was subjected to 8–10% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and separated proteins were transferred 
to Immobilon-P PolyVinylidene DiFluoride (PVDF) 
membranes (Merck Millipore, Billerica, MA). The 
membranes were incubated with anti-EGFR, anti-
PTEN, anti-Akt, anti-KRAS, anti-TP53, anti-LKB1 
antibodies (1:1,000 dilution, Cell signaling technology, 
Beverly, MA) and β-actin antibody (1:2,000 dilution, 
Sigma-Aldrich, St. Louis, MO). Primary antibodies were 
detected using horseradish peroxidase (HRP)-conjugated 
secondary antibodies (1:1,000 dilution, anti-mouse IgG 
and anti-Rabbit IgG respectively; GE Healthcare Bio-
sciences Amersham, Diegem, Belgium, UK). The mem-
branes were subjected to chemiluminescence detection 
assay using ECL Prime Western Blotting Detection 
Reagents (GE Healthcare Bio-sciences Amersham).
Cell proliferation assay
Cell proliferation after treatment with 0, 0.01, 0.1 and 1.0 
µM cetuximab for 6 days was detected by water-soluble 
tetrazolium salt (WST-8) for colorimetric cell viability 
assay (Dojindo Molecular Technologies, Kumamoto, 
Japan). The procedure was performed according to the 
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manufacture’s instruction. The absorbance at 450 nm 
with a reference wave length of 655 nm was measured 
by a microplate reader, Sunrise RAINBOW (Tecan 
Trading AG, Männedorf Switzerland).
Active caspase-3/7 assay
Active caspase-3/7 was measured using a homogeneous 
luminescent method with Caspase-3/7 Glo assay kit 
(Promega, Madison, WI). The operating procedure was 
performed according to the manufacture’s instruction. 
After the cell lines were transfected with EGFR siRNA 
and treated with 0, 0.01, 0.1 and 1.0 µM cetuximab 
for 24 h, the luminescence was measured by using a 
multifunctional microplate reader, Infi nite F500 (Tecan 
Trading AG).
Migration and invasion assay
The in vitro migration assay used an HTS Transwell-96 
permeable support with 8 µm pore polyester membrane 
(Corning Incorporated, NY). The in vitro invasion as-
says were performed using HTS Transwell-96 well plate 
with Matrigel-coated filters (Corning Incorporated). 
Cell lines were seeded into the upper 96 well of the 
plate and exposed to 0, 0.01, 0.1 and 1.0 µM cetuximab, 
whereas 10% FBS medium was added into the lower 
well followed by incubation for 42 h. Non-migratory and 
non-invasive cells stayed in the upper membrane and 
migratory and invasive cells passed through basement 
membrane layer and cling to the bottom of the insert 
membrane. Migratory and invasive cells were dissociat-
ed from membrane by the detachment buffer and were 
lysed by the lysis buffer. Finally, the lysates were stained 
with CyQuant GR Dye (Invitrogen, Carlsbad) and the 
fluorescence produced were measured (excitation: 485 
nm/emission: 525 nm) using multifunctional microplate 
reader, Infi nite F500 (Tecan Trading AG).
Statistical analysis
All experiments were performed in triplicate. The values 
were represented as mean ± SD (standard deviation). 
Statistical analyses were performed by one-way ANOVA 
(analysis of variance) with Bonferroni’s test using SPSS 
Statistics 25 (IBM Japan, Tokyo, Japan). The result was 
considered statistically signifi cant if P < 0.05.
RESULTS
Gene status of cell line
The gene status of EGFR, PTEN, KRAS, TP53 and 
LKB1 in all NSCLC cell lines used in this study are 
Table 1. Gene atatus of NSCLC cell lines
Cell EGFR KRAS PTEN TP53 LKB1
A549 Adenocarcinoma WT14, 21, 41 mutant (G12S)14, 21, 22 WT41 WT41, 42 mutant (Q37Ter)16, 21, 22, 31, 32
Lu99 Giant cell carcinoma WT14, 21, 40, 41 mutant (G12C)14 mutant mutant43 WT21
86-2 Large cell carcinoma WT14, 40 WT WT mutant43 mutant
Sq19 Squamous cell carcinoma WT40 WT mutant mutant mutant
Ma10 Adenocarcinoma WT14, 21 WT WT41 mutant (c.734G > T)41, 42, 43 WT
21
EGFR, epidermal growth factor receptor; KRAS,v-ki-ras2 kirsten rat sarcoma viral oncogene homolog; LKB1, liver kinase B1; NSCLC, non-
small cell lung cancer; PTEN, phosphatase and tensin homolog deleted from chromosome 10; TP53, tumor protein p53; WT, wild type
LKB1
PTEN
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β-actin
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N.	Miyake	et	al.,	p.	27
Fig. 1. Protein expression in NSCLC cell lines. Protein expres-
sion of EGFR, PTEN, KRAS, Akt, LKB1, TP53 and β-actin in 
NSCLC cell lines were analyzed by western blotting. Akt, v-akt 
murine thymoma viral oncogene; EGFR, epidermal growth factor 
receptor; KRAS, v-ki-ras2 kirsten rat sarcoma viral oncogene 
homolog; LKB1, liver kinase B1; NSCLC, non-small cell lung 
cancer; PTEN, phosphatase and tensin homolog deleted from 
chromosome 10; TP53, tumor protein p53.
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Fig. 2. EGFR expression in NSCLC cell lines after EGFR siRNA 
treatment. Down regulation of EGFR expression was observed 
by western blotting. EGFR, epidermal growth factor receptor; 
NSCLC, non-small cell lung cancer; siRNA, small interfering 
RNA.
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Fig. 3. Effect of cetuximab on cell proliferation of NSCLC cell lines. NSCLC cell lines were treated with 0, 0.01, 0.1 and 1.0 µM cetux-
imab for 6 days, and cell proliferation of was assessed using WST-8 cell proliferation assay kit. NSCLC, non-small cell lung cancer; WST-
8, water-soluble tetrazolium salt.
listed in Table 1. We examined KRAS gene status in 86-
2, Sq19 and Ma10, PTEN gene status in Lu99, 86-2 and 
Sq19, TP53 gene status in Sq19, and LKB1 gene status 
in 86-2 and Sq19 using PCR and direct sequencing with 
sequence specifi c primers published elsewhere.16–18 The 
remaining gene status of the cell lines were cited from a 
published data as indicated in the table 1. All cell lines 
exhibited wild-type EGFR, whereas KRAS, PTEN, TP53
and LKB1 were mutated in A549 and Lu99; Lu99 and 
Sq19; Lu99, 86-2, Sq19 and Ma10; and A549, 86-2 and 
Sq19, respectively.
Protein expression of NSCLC cell lines
The expression of EGFR, PTEN, Akt, KRAS, TP53 and 
LKB1 proteins in all NSCLC cell lines was examined 
using western blotting (Fig.1). EGFR, KRAS and Akt 
were equally expressed in all cell lines. However, PTEN 
was not expressed in Sq19 cells, and the expression of 
Akt and KRAS were comparable with other cell lines. 
LKB1 was not expressed in A549 and Sq19 cells, and 
TP53 was not expressed in A549 and Lu99 cells.
Effect of EGFR siRNA on EGFR expression
Next, we tested the effect of EGFR specifi c siRNA on 
the expression of EGFR in all cell lines. As shown in 
Fig. 2, the expression of EGFR was almost suppressed 
by EGFR specific siRNA, whereas negative control 
siRNA that consists of non-targeting 20–25 bp nucleotide 
strands had no effect on the expression of EGFR. The 
proliferation of the cells transfected with EGFR siRNA 
was not different from those of the cells transfected with 
negative control siRNA (data not shown).
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Effect of cetuximab on cell proliferation in NSCLC 
cell lines
We evaluated the effect of cetuximab on the cell growth 
in NSCLC cell lines. The number of NSCLC cells 
after cetuximab treatment (0, 0.01, 0.1 and 1.0 µM) was 
measured for 6 days using a colorimetric WST-8 assay. 
As shown in Fig. 3, cetuximab has no effect on the pro-
liferation in all NSCLC cell lines. Therefore, it was con-
fi rmed that all the cell lines studied here are cetuximab-
N.	Miyake	et	al.,	p.	30	
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Fig. 4. Inhibition of cell proliferation by the combination treatment of cetuximab with EGFR siRNA. Cells were treated with the combi-
nation of 0, 0.01, 0.1 and 1.0 µM cetuximab and EGFR siRNA for 6 days. Cell proliferation was assessed using WST-8 cell proliferation 
assay kit. *P < 0.05 compared the combination of cetuximab and negative control siRNA by one-way ANOVA with Bonferroni’s multiple 
comparison test using SPSS Statistics 25. ANOVA, analysis of variance; EGFR, epidermal growth factor receptor; NSCLC, non-small 
cell lung cancer; siRNA, small interfering RNA; WST-8, water-soluble tetrazolium salt.
Fig. 5. Apoptosis induction by the combination treatment of cetuximab and EGFR siRNA. Cells were treated with the combination of 
cetuximab (0, 0.01, 0.1 and 1.0 µM) and EGFR siRNA for 24 h. The production of active caspase 3/7 as a surrogate marker of apoptosis 
was assessed using Caspase-3/7 Glo assay kit. *P < 0.05 compared the combination of cetuximab and negative control siRNA by one-way 
ANOVA with Bonferroni’s multiple comparison test using SPSS Statistics 25. ANOVA, analysis of variance; EGFR, epidermal growth 
factor receptor; NSCLC, non-small cell lung cancer; siRNA, small interfering RNA.
resistant cell lines.
Effect of combination treatment of cetuximab and 
EGFR siRNA on cell proliferation
Furthermore, to test the effect of EGFR downregulation 
on the cetuximab-resistant cells, we evaluated the effect 
of cetuximab on NSCLC cell proliferation in the absence 
or presence of EGFR specifi c siRNA. As shown in Fig. 4, 
the combination of cetuximab with EGFR siRNA showed 
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Fig. 6. Alteration of migration abilities of NSCLC cells by the combination treatment of cetuximab and EGFR siRNA. The NSCLC cell 
lines were treated with cetuximab (0, 0.01, 0.1 and 1.0 µM) and EGFR siRNA for 42 h. Cell migration was evaluated after the combi-
nation treatment in vitro. No significant alteration of migration was observed compared with the treatment with cetuximab and negative 
control siRNA. EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; siRNA, small interfering RNA.
Fig. 7. Alteration of invasion abilities of NSCLC cells by the combination treatment of cetuximab and EGFR siRNA. The NSCLC cell 
lines were treated with (0, 0.01, 0.1 and 1.0 µM) cetuximab and EGFR siRNA for 42 h. Cell invasion was evaluated after the combination 
treatment in vitro. *P < 0.05 compared the combination of cetuximab and negative control siRNA by one-way ANOVA with Bonferroni’s 
multiple comparison test using SPSS Statistics 25. ANOVA, analysis of variance; EGFR, epidermal growth factor receptor; NSCLC, non-
small cell lung cancer; siRNA, small interfering RNA.
significant suppression of cell proliferation in 86-2, Sq19 
and Ma10 NSCLC cell lines. These cell lines have wild-
type KRAS (Table 1). The cell lines that have mutated 
KRAS were found to be insensitive to the combination 
treatment. These data suggested that the KRAS status is 
a possible biomarker for the combination treatment of 
cetuximab with EGFR siRNA.
Effect of combination treatment of cetuximab and 
EGFR siRNA on apoptosis
After exploring the mechanism underlying the inhibition 
of cell proliferation by the combination treatment of 
cetuximab and EGFR siRNA, we tested theses effect on 
apoptosis in each cell line. In this assay, we measured 
the production of active caspase-3/7 as a surrogate mark-
er of apoptosis. As shown in Fig. 5, the combination 
treatment induced significant apoptosis in A549, 86-2 
and Ma10 cell lines. These cell lines harbor wild-type 
PTEN, whereas the cell lines in which apoptosis was 
not induced by the combination treatment have mutated 
PTEN. As wild-type PTEN was reported to promote 
apoptosis,19 the combined effect of wild-type PTEN and 
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the combination treatment might facilitate the induction 
of apoptosis. Moreover, induction of apoptosis by the 
combination treatment is a possible mechanism for the 
inhibition of cell proliferation in 86-2 and Ma10 cell 
lines.
Effect of combination treatment of cetuximab 
and EGFR siRNA on migration and invasion.
Since cell migration and invasion are the hallmarks of 
cancer cells,20 we evaluated the effect of the combina-
tion treatment of cetuximab with EGFR siRNA on cell 
migration and invasion. Cell migration was not affected 
by the combination treatment (Fig. 6). Cell invasion 
was suppressed by the combination treatment of 0.01 
μM cetuximab and EGFR siRNA; however, it was 
not affected by the combination treatment of the other 
concentrations of cetuximab and EGFR siRNA (Fig. 7). 
Therefore, we concluded that the combination treatment 
mostly affects EGFR pathways that relate to cell prolif-
eration and apoptosis.
DISCUSSION
In this study, we explored the effect of the combination 
treatment of cetuximab with EGFR siRNA in NSCLC 
cell lines with wild-type EGFR. We found that this 
combination treatment suppressed the proliferation of 
cells that carried wild-type KRAS. Therefore, the muta-
tional status of KRAS might be a possible biomarker of 
this combination treatment. In addition, we also showed 
that combination treatment induces apoptosis, which 
suppresses the proliferation of cells that carry wild-type 
PTEN. These observations suggest that the combination 
therapy of cetuximab with EGFR siRNA is promising 
for the treatment of NSCLC using KRAS and PTEN 
gene status as biomarkers.
 A number of signaling molecules are involved in 
cancer development. These genes are classified into two 
categories; oncogenes that promote cancer development 
and tumor suppressor genes that inhibit cancer develop-
ment. EGFR pathways, which play a vital role in cancer 
development, mainly regulate cell proliferation signals; 
many genes downstream of EGFR are known oncogenes 
and tumor suppressor genes. KRAS is the oncogene and 
PTEN, TP53, and LKB1 are the tumor suppressor genes 
involved in this pathway (Fig. 8). Dysregulation of these 
molecules by gene mutation or alternation of protein 
expression is reported to promote cancer development. 
For example, KRAS mutation constitutively activates 
the EGFR signaling pathway and promote cell prolif-
eration.21–25 PTEN is the tumor suppressor molecule of 
PI3K-Akt pathway that regulates cell proliferation, cell 
growth, and inhibition of apoptosis.26 Mutation or loss 
of PTEN is reported to inhibit apoptosis, which leads to 
cell proliferation.18, 27, 28 TP53 is a multifunctional protein 
that is activated owing to cell-physiologic stress and 
prevents cancer development via the induction of apop-
tosis, cell cycle arrest, DNA repair, and the inhibition 
of angiogenesis.29 Indeed, TP53 mutation is reported to 
reduce apoptosis in cancer cells.30 LKB1 inhibits activa-
tion of mTOR signal functioning in the downstream of 
PI3K-Akt pathway, and functional loss of LKB1 leads to 
cell proliferation.22, 31–33
 In this study, we examined five NSCLC cell lines. 
Since, these cell lines have wild-type EGFR, the aber-
rant proliferative activity of these cancer cells is depen-
dent on the EGFR downstream molecules. KRAS is ab-
errantly activated by mutations in A549 and Lu99 cells 
and is the cause of the abnormal activity of the growth 
regulating function of these cancer cell lines. Moreover, 
we showed that TP53 was inactivated in all cell lines 
by defective expression (A549) or gene mutation (Lu99, 
86-2, Sq19 and Ma10), and one or two additional tumor 
suppressor genes are inactivated by mutation or defec-
tive expression in each cell line. These diverse variety 
of inactivation of tumor suppressor genes may strongly 
Fig. 8. EGFR downstream pathways tested in this study. Tested 
molecules that activate EGFR pathway are circled with a contin-
uous line, and tested molecules that negatively regulate this path-
way are circled with a dashed line. Akt, v-akt murine thymoma 
viral oncogene; EGFR, epidermal growth factor receptor; ERK, 
extracellular signal-regulated kinase; KRAS, v-ki-ras2 kirsten rat 
sarcoma viral oncogene homolog; LKB1, liver kinase B1; MEK, 
mitogen-activated protein kinase/extracellular signal-regulated ki-
nase; mTOR, mammalian target of rapamycin; PI3K, phosphoinositol-
3-kinase; PTEN, phosphatase and tensin homolog deleted from 
chromosome 10; RAF, v-raf murine sarcoma viral oncogene 
homolog; siRNA, small interfering RNA; SOS, son of sevenless; 
TP53, tumor protein p53.
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contribute to the cancer development.
 Dysregulation of oncogenes and tumor suppressor 
genes are considered as the biomarkers of molecular 
targeted therapy in cancer. In the anti-EGFR therapy, 
somatic mutation of tyrosine kinase domain of EGFR 
that renders aberrant activation was revealed as potent 
predictors of response to EGFR-TKIs.34, 35 In addition, 
increased EGFR copy number36 and KRAS mutation37 
were reported as negative predictors of EGFR-TKI. 
For cetuximab, wild-type KRAS was reported to be a 
predictor of colorectal cancer responsiveness,38 however, 
it was reported that the KRAS mutation status was not 
useful in predicting the responsiveness for cetuximab 
in NSCLC patient.39 In the NSCLC cell lines with wild-
type EGFR, we showed that wild-type KRAS would be 
a common characteristic of the cells that are sensitive 
for the combination treatment of cetuximab with EGFR 
siRNA. To our knowledge, this is among the first studies 
that identified a biomarker of this combination treatment 
for NSCLC cells with wild-type EGFR.
 There are several limitations in this study. First, we 
have presented data showing that one of the mechanisms 
of the susceptibility to the combination treatment of 
cetuximab and EGFR siRNA was the induction of 
apoptosis in two of three sensitive cell lines (86-2, 
Ma10). However, in the other sensitive cell line (Sq19), 
the mechanism was unclear, and a more extensive study 
of the other signaling molecules affected by this combi-
nation treatment is needed. Second, this was an in vitro 
study using NSCLC cell lines, and its results need to be 
validated using animal experiments and clinical testing 
to enable the practical application of the combination 
treatment of cetuximab with EGFR siRNA.
 In conclusion, EGFR targeted treatment using the 
combination of cetuximab and EGFR siRNA is effec-
tive even in the NSCLC cell lines harboring wild-type 
EGFR. A possible biomarker of response to this com-
bination treatment is wild-type KRAS, and one of the 
mechanisms of action is induction of apoptosis in cells 
with wild-type PTEN. The combination treatment of 
cetuximab and EGFR siRNA may be a new therapeutic 
potential in NSCLC patients.
The authors declare no conflict of interest.
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